← Dashboard
Aug 12, 2026 11:40 PM ET
Signal
FDA/Bio
DEFINIUM THERAPEUTICS, INC. (DFTX) DISCUSSES PHASE 3 VOYAGE STUDY TOPLINE RESULTS FOR DT120 IN GENERALIZED ANXIETY DISORDER TRANSCRIPT - SEEKINGALPHA
Phase 3 topline results for DT120 in anxiety disorder present key catalyst.
What changed
Phase 3 topline results for DT120 in anxiety disorder present key catalyst.
Why it matters
Phase 3 topline results for DT120 in anxiety disorder present key catalyst. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
In reversal, American Cancer Society urges routine prostate cancer screening →
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →
PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →